Select Page

Bachelor of Science in Architecture and Practice

At its meeting of 7 September 2020, the Board decided that the above qualification should be prescribed for the period 30 November 2020 to 29 November 2024* under Section 4(1)(a) of the Architects Act 1997 for the purposes of entry onto the United Kingdom Register of Architects.

Prescription is subject to the Standard Conditions set out in the Board’s Procedures, namely:

a. University College London’s Bachelor of Science in Architecture and Practice with Honours (three years, full-time) qualification should be prescribed for the period from 30 November 2020 to 29 November 2024.*

b. Prescription of the qualification shall be by reference to the Programme Specification – submitted with the application of 4 April 2019 – for the Bachelor of Science in Architecture and Practice with Honours (three years, full-time) qualification. No change may be made to the title of any qualification, or material change to the content so defined within a programme specification (allowing for normal course development) without first obtaining the written permission of the Board.

c. Annually by 31 March – commencing on 31 March 2021 – the institution will be required to provide the Board with information of the nature set out in Appendix 2 of its Procedures to enable the Board to see that:

i. All its Criteria and the relevant requirements set out in Article 46 (or Article 47) of the Mutual Recognition of Professional Qualifications Directive [2005/36/EC] have been attained by all students awarded the prescribed qualification;

ii. Adequate systems are in place to ensure that all the Board’s Criteria will be met by students for the period of prescription;

iii. The institution’s resources remain as set out in the application and are adequate; and

iv. All of the factors referred to in Sections 2.2 and 2.3 of the Procedures continue to be demonstrated, and any conditions of prescription continue to be met.

d. The institution will ensure that appropriate procedures will be maintained so that all students undertaking a prescribed qualification are fully informed of the extent of the application of that qualification to entitlement to registration as an architect in circumstances in which the student lacks a required antecedent qualification, e.g. Part 2 without Part 1.

e. Following each and every set of examinations, the institution shall be required to submit to the Board its pass lists of graduating cohorts who have received the prescribed award.


The Board was confident that:

i. The course proposal – including the educational aims, the intended learning outcomes, the assessments etc – has been designed with the clear aim of ensuring that all those who receive the qualification will have met all the Criteria;

ii. Systems are in place to ensure that all Criteria will be met by all students receiving the qualification for the period of prescription; and

iii. The institution has adequate resources to maintain and, where appropriate, increase the achievements of students meeting all the Criteria.


At its meeting of 24 May 2023, the Board agreed that the following additional condition should be attached to prescription of the qualification:

  • That by 30 September 2023, and as part of its future annual monitoring submissions – commencing 31 March 2024 – the institution must provide the following information:
    • An update on the actions in response to the Howlett Brown report continuing from the information submitted on 31 March 2023; and
    • An update on the metrics the institution has developed in order to determine whether the actions undertaken have been successful in addressing the concerns raised in the Howlett Brown report, and the outcomes of those metrics.

The Howlett Brown report raised significant concerns that the institution was not meeting the Board’s requirements in relation to equality and diversity. The submission of the information set out within the additional condition will provide the Board with assurance that the institution is committed to addressing and resolving the concerns raised within the report, and that it has been successful in doing so.


* At its meeting of 27 February 2023, the Board agreed to extend prescription until 31 December 2028.